Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2017

01-11-2017 | Epidemiology

Relationship between mammographic calcifications and the clinicopathologic characteristics of breast cancer in Western China: a retrospective multi-center study of 7317 female patients

Authors: Ke Zheng, Jin-Xiang Tan, Fan Li, Yu-Xian Wei, Xue-Dong Yin, Xin-Liang Su, Hong-Yuan Li, Qi-Lun Liu, Bin-Lin Ma, Jiang-Hua Ou, Hui Li, Sui-Sheng Yang, Ai-Mei Jiang, Qing Ni, Jian-Lun Liu, Jin-Ping Liu, Hong Zheng, Zhang-Jun Song, Ling Wang, Jian-Jun He, Tian-Ning Zou, Jun Jiang, Guo-Sheng Ren

Published in: Breast Cancer Research and Treatment | Issue 2/2017

Login to get access

Abstract

Background and purpose

Limited information is available regarding the correlations between mammographic calcifications and the epidemiological features of patients with breast cancer living different lifestyles in Western China. Thus, this study aimed to investigate the relationship between mammographic calcifications and the epidemiological characteristics of female patients with breast cancer in Western China.

Methods

This was a hospital-based, retrospective, multi-center epidemiological study of patients with breast cancer. Using the Western China Clinical Cooperation Group (WCCCG) database, we obtained the records of 7317 patients (with mammographic data) diagnosed with breast cancer between March 2011 and June 2016. These patients were divided into Groups I (mass alone) and II (mass combined with calcification), and their clinical and pathological data were compared.

Results

A total of 4211 patients were enrolled in Group I, and 3106 patients were enrolled in Group II. The tumors in Group II were more likely to be larger (P < 0.0001), higher grade (P = 0.0029), estrogen receptor (ER)+/progesterone receptor (PR)− (P = 0.0319), and human epidermal growth factor receptor 2 (HER-2)-positive (P < 0.0001), and to have axillary lymph node metastasis (P = 0.0033) than those in Group I. Regarding treatment, patients in Group II were more likely to have undergone chemotherapy (P = 0.0108) and anti-HER2 therapy (P = 0.0102), whereas patients in Group I were more likely to have undergone endocrine therapy (P < 0.0001).

Conclusions

In conclusion, mammographic calcifications in tumors were associated with distinct clinicopathologic characteristics and aggressive treatments.
Literature
1.
go back to reference Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66(4):271–289. doi:10.3322/caac.21349 CrossRefPubMed Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66(4):271–289. doi:10.​3322/​caac.​21349 CrossRefPubMed
2.
go back to reference Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM (2009) Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat 117(2):409–416. doi:10.1007/s10549-008-0303-z CrossRefPubMed Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM (2009) Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat 117(2):409–416. doi:10.​1007/​s10549-008-0303-z CrossRefPubMed
5.
go back to reference Tabar L, Chen HH, Duffy SW, Yen MF, Chiang CF, Dean PB, Smith RA (2000) A novel method for prediction of long-term outcome of women with T1a, T1b, and 10–14 mm invasive breast cancers: a prospective study. Lancet 355(9202):429–433CrossRefPubMed Tabar L, Chen HH, Duffy SW, Yen MF, Chiang CF, Dean PB, Smith RA (2000) A novel method for prediction of long-term outcome of women with T1a, T1b, and 10–14 mm invasive breast cancers: a prospective study. Lancet 355(9202):429–433CrossRefPubMed
6.
go back to reference Gajdos C, Tartter PI, Bleiweiss IJ, Hermann G, de Csepel J, Estabrook A, Rademaker AW (2002) Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics. Ann Surg 235(2):246–251CrossRefPubMedPubMedCentral Gajdos C, Tartter PI, Bleiweiss IJ, Hermann G, de Csepel J, Estabrook A, Rademaker AW (2002) Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics. Ann Surg 235(2):246–251CrossRefPubMedPubMedCentral
7.
go back to reference Evans AJ, Pinder SE, Ellis IO, Sibbering DM, Elston CW, Poller DN, Wilson AR (1994) Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team. Clin Radiol 49(8):559–562CrossRefPubMed Evans AJ, Pinder SE, Ellis IO, Sibbering DM, Elston CW, Poller DN, Wilson AR (1994) Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team. Clin Radiol 49(8):559–562CrossRefPubMed
10.
go back to reference Karamouzis MV, Likaki-Karatza E, Ravazoula P, Badra FA, Koukouras D, Tzorakoleftherakis E, Papavassiliou AG, Kalofonos HP (2002) Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. Int J Cancer 102(1):86–90. doi:10.1002/ijc.10654 CrossRefPubMed Karamouzis MV, Likaki-Karatza E, Ravazoula P, Badra FA, Koukouras D, Tzorakoleftherakis E, Papavassiliou AG, Kalofonos HP (2002) Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. Int J Cancer 102(1):86–90. doi:10.​1002/​ijc.​10654 CrossRefPubMed
11.
go back to reference Tabar L, Tony Chen HH, Amy Yen MF, Tot T, Tung TH, Chen LS, Chiu YH, Duffy SW, Smith RA (2004) Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma. Cancer 101(8):1745–1759. doi:10.1002/cncr.20582 CrossRefPubMed Tabar L, Tony Chen HH, Amy Yen MF, Tot T, Tung TH, Chen LS, Chiu YH, Duffy SW, Smith RA (2004) Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma. Cancer 101(8):1745–1759. doi:10.​1002/​cncr.​20582 CrossRefPubMed
12.
go back to reference Jiang L, Ma T, Moran MS, Kong X, Li X, Haffty BG, Yang Q (2011) Mammographic features are associated with clinicopathological characteristics in invasive breast cancer. Anticancer Res 31(6):2327–2334PubMed Jiang L, Ma T, Moran MS, Kong X, Li X, Haffty BG, Yang Q (2011) Mammographic features are associated with clinicopathological characteristics in invasive breast cancer. Anticancer Res 31(6):2327–2334PubMed
13.
14.
go back to reference Palka I, Ormandi K, Gaal S, Boda K, Kahan Z (2007) Casting-type calcifications on the mammogram suggest a higher probability of early relapse and death among high-risk breast cancer patients. Acta Oncol 46(8):1178–1183. doi:10.1080/02841860701373611 CrossRefPubMed Palka I, Ormandi K, Gaal S, Boda K, Kahan Z (2007) Casting-type calcifications on the mammogram suggest a higher probability of early relapse and death among high-risk breast cancer patients. Acta Oncol 46(8):1178–1183. doi:10.​1080/​0284186070137361​1 CrossRefPubMed
16.
go back to reference Wang K, Ren Y, Li H, Zheng K, Jiang J, Zou T, Ma B, Li H, Liu Q, Ou J, Wang L, Wei W, He J, Ren G (2016) Comparison of clinicopathological features and treatments between young (</=40 years) and older (> 40 years) female breast cancer patients in West China: a retrospective, epidemiological, multicenter, case only study. PLoS ONE 11(3):e0152312. doi:10.1371/journal.pone.0152312 CrossRefPubMedPubMedCentral Wang K, Ren Y, Li H, Zheng K, Jiang J, Zou T, Ma B, Li H, Liu Q, Ou J, Wang L, Wei W, He J, Ren G (2016) Comparison of clinicopathological features and treatments between young (</=40 years) and older (> 40 years) female breast cancer patients in West China: a retrospective, epidemiological, multicenter, case only study. PLoS ONE 11(3):e0152312. doi:10.​1371/​journal.​pone.​0152312 CrossRefPubMedPubMedCentral
18.
go back to reference Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356(3):227–236. doi:10.1056/NEJMoa062790 CrossRefPubMed Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356(3):227–236. doi:10.​1056/​NEJMoa062790 CrossRefPubMed
19.
go back to reference Aminololama-Shakeri S, Abbey CK, Gazi P, Prionas ND, Nosratieh A, Li CS, Boone JM, Lindfors KK (2016) Differentiation of ductal carcinoma in situ from benign micro-calcifications by dedicated breast computed tomography. Eur J Radiol 85(1):297–303. doi:10.1016/j.ejrad.2015.09.020 CrossRefPubMed Aminololama-Shakeri S, Abbey CK, Gazi P, Prionas ND, Nosratieh A, Li CS, Boone JM, Lindfors KK (2016) Differentiation of ductal carcinoma in situ from benign micro-calcifications by dedicated breast computed tomography. Eur J Radiol 85(1):297–303. doi:10.​1016/​j.​ejrad.​2015.​09.​020 CrossRefPubMed
21.
go back to reference James JJ, Evans AJ, Pinder SE, Macmillan RD, Wilson AR, Ellis IO (2003) Is the presence of mammographic comedo calcification really a prognostic factor for small screen-detected invasive breast cancers? Clin Radiol 58(1):54–62CrossRefPubMed James JJ, Evans AJ, Pinder SE, Macmillan RD, Wilson AR, Ellis IO (2003) Is the presence of mammographic comedo calcification really a prognostic factor for small screen-detected invasive breast cancers? Clin Radiol 58(1):54–62CrossRefPubMed
22.
go back to reference Nyante SJ, Lee SS, Benefield TS, Hoots TN, Henderson LM (2017) The association between mammographic calcifications and breast cancer prognostic factors in a population-based registry cohort. Cancer 123(2):219–227. doi:10.1002/cncr.30281 CrossRefPubMed Nyante SJ, Lee SS, Benefield TS, Hoots TN, Henderson LM (2017) The association between mammographic calcifications and breast cancer prognostic factors in a population-based registry cohort. Cancer 123(2):219–227. doi:10.​1002/​cncr.​30281 CrossRefPubMed
23.
go back to reference Evans AJ, Pinder SE, James JJ, Ellis IO, Cornford E (2006) Is mammographic spiculation an independent, good prognostic factor in screening-detected invasive breast cancer? AJR Am J Roentgenol 187(5):1377–1380. doi:10.2214/AJR.05.0725 CrossRefPubMed Evans AJ, Pinder SE, James JJ, Ellis IO, Cornford E (2006) Is mammographic spiculation an independent, good prognostic factor in screening-detected invasive breast cancer? AJR Am J Roentgenol 187(5):1377–1380. doi:10.​2214/​AJR.​05.​0725 CrossRefPubMed
24.
go back to reference Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res BCR 9(1):R6. doi:10.1186/bcr1639 CrossRefPubMed Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res BCR 9(1):R6. doi:10.​1186/​bcr1639 CrossRefPubMed
25.
go back to reference Schiavon G, Smith IE (2014) Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res BCR 16(2):206CrossRefPubMed Schiavon G, Smith IE (2014) Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res BCR 16(2):206CrossRefPubMed
27.
go back to reference Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182CrossRefPubMed Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182CrossRefPubMed
29.
go back to reference Martin M, Sanchez-Rovira P, Munoz M, Baena-Canada JM, Mel JR, Margeli M, Ramos M, Martinez E, Garcia-Saenz JA, Casado A, Jaen AM, Gonzalez-Farre X, Escudero MJ, Rodriguez-Martin C, Carrasco E, Geicam (2011) Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Ann Oncol 22(12):2591–2596. doi:10.1093/annonc/mdr024 CrossRefPubMed Martin M, Sanchez-Rovira P, Munoz M, Baena-Canada JM, Mel JR, Margeli M, Ramos M, Martinez E, Garcia-Saenz JA, Casado A, Jaen AM, Gonzalez-Farre X, Escudero MJ, Rodriguez-Martin C, Carrasco E, Geicam (2011) Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Ann Oncol 22(12):2591–2596. doi:10.​1093/​annonc/​mdr024 CrossRefPubMed
31.
go back to reference Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thurlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, Collins J, International Breast Cancer Study Group Trials I VII (2003) Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 21(7):1205–1213. doi:10.1200/JCO.2003.03.130 CrossRefPubMed Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thurlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, Collins J, International Breast Cancer Study Group Trials I VII (2003) Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 21(7):1205–1213. doi:10.​1200/​JCO.​2003.​03.​130 CrossRefPubMed
33.
go back to reference Barnes DM, Camplejohn RS (1996) P53, apoptosis, and breast cancer. J Mammary Gland Biol Neoplasia 1(2):163–175CrossRefPubMed Barnes DM, Camplejohn RS (1996) P53, apoptosis, and breast cancer. J Mammary Gland Biol Neoplasia 1(2):163–175CrossRefPubMed
Metadata
Title
Relationship between mammographic calcifications and the clinicopathologic characteristics of breast cancer in Western China: a retrospective multi-center study of 7317 female patients
Authors
Ke Zheng
Jin-Xiang Tan
Fan Li
Yu-Xian Wei
Xue-Dong Yin
Xin-Liang Su
Hong-Yuan Li
Qi-Lun Liu
Bin-Lin Ma
Jiang-Hua Ou
Hui Li
Sui-Sheng Yang
Ai-Mei Jiang
Qing Ni
Jian-Lun Liu
Jin-Ping Liu
Hong Zheng
Zhang-Jun Song
Ling Wang
Jian-Jun He
Tian-Ning Zou
Jun Jiang
Guo-Sheng Ren
Publication date
01-11-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4406-2

Other articles of this Issue 2/2017

Breast Cancer Research and Treatment 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine